Overexpression of LBX2 associated with tumor progression and poor prognosis in colorectal cancer
Colorectal cancer (CRC) is one of the most common carcinomas with high morbidity and mortality worldwide. However, the underlying molecular mechanisms of CRC are unclear. The aim of the present study was to establish the role that overexpression of LBX2 serves in CRC and to investigate the associate...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2020-06, Vol.19 (6), p.3751-3760 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3760 |
|---|---|
| container_issue | 6 |
| container_start_page | 3751 |
| container_title | Oncology letters |
| container_volume | 19 |
| creator | Huang, Xiaodong Yang, Yujie Yang, Chao Li, Huali Cheng, Huangrong Zheng, Yongbin |
| description | Colorectal cancer (CRC) is one of the most common carcinomas with high morbidity and mortality worldwide. However, the underlying molecular mechanisms of CRC are unclear. The aim of the present study was to establish the role that overexpression of LBX2 serves in CRC and to investigate the associated biological pathways. The difference in the expression levels of LBX2 between CRC tissues and adjacent normal colorectal tissues was assessed using the Oncomine database and Tumor Immune Estimation Resource. The expression levels of LBX2 and its prognostic significance in CRC were analyzed using a t-test and χ
test using data from The Cancer Genome Atlas database. The Kaplan-Meier method and Cox regression analysis were used to estimate the prognostic value of LBX2 in CRC. Furthermore, the potential mechanisms of LBX2 dysregulation and its underlying molecular mechanisms in CRC were investigated using Gene Set Enrichment Analysis (GSEA). LBX2 expression levels were significantly upregulated in CRC samples compared with corresponding normal colorectal tissues (P |
| doi_str_mv | 10.3892/ol.2020.11489 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7202318</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A626124919</galeid><sourcerecordid>A626124919</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-11a45fdce6b1dcc34696f2e6ecbb1e3a57443f6d89349e5fe321210bdd0836383</originalsourceid><addsrcrecordid>eNptks1vFCEYxidGY5u1R6-GxMR42XWAGRYuJm1TP5JNetHEGzLMO7s0DO8IM1X_-zJ2u3aNcIDA732Ah6coXtJyxaVi79CvWMnKFaWVVE-KU7pWbElLyZ4e5uvqpDhL6abMrRZUSvG8OOGMS8aZPC2-X99ChF9DhJQcBoId2Vx8Y8SkhNaZEVry0407Mk49RjJE3D6QJrRkwP1iwOQScYFY9BjBjsYTa4KF-KJ41hmf4Gw_LoqvH66-XH5abq4_fr483yxtTfm4pNRUdddaEA1treWVUKJjIMA2DQVu6nVV8U60UvFKQd0BZ5TRsmnbUnLBJV8U7-91h6npIQuFMRqvh-h6E39rNE4f7wS301u81evsIKezwNu9QMQfE6RR9y5Z8N4EwClpVmUDuZL5uovi9T_oDU4x5OfNFK1VrYT8S22NB-1Ch_lcO4vqc8EEZZWiKlOr_1C5t9A7iwE6l9ePCt48KtiB8eMuoZ_G_CnpGFzegzZiShG6gxm01HN8NHo9x0f_iU_mXz128EA_hIXfAY-BvzU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2401595968</pqid></control><display><type>article</type><title>Overexpression of LBX2 associated with tumor progression and poor prognosis in colorectal cancer</title><source>Spandidos Publications Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Huang, Xiaodong ; Yang, Yujie ; Yang, Chao ; Li, Huali ; Cheng, Huangrong ; Zheng, Yongbin</creator><creatorcontrib>Huang, Xiaodong ; Yang, Yujie ; Yang, Chao ; Li, Huali ; Cheng, Huangrong ; Zheng, Yongbin</creatorcontrib><description><![CDATA[Colorectal cancer (CRC) is one of the most common carcinomas with high morbidity and mortality worldwide. However, the underlying molecular mechanisms of CRC are unclear. The aim of the present study was to establish the role that overexpression of LBX2 serves in CRC and to investigate the associated biological pathways. The difference in the expression levels of LBX2 between CRC tissues and adjacent normal colorectal tissues was assessed using the Oncomine database and Tumor Immune Estimation Resource. The expression levels of LBX2 and its prognostic significance in CRC were analyzed using a t-test and χ
test using data from The Cancer Genome Atlas database. The Kaplan-Meier method and Cox regression analysis were used to estimate the prognostic value of LBX2 in CRC. Furthermore, the potential mechanisms of LBX2 dysregulation and its underlying molecular mechanisms in CRC were investigated using Gene Set Enrichment Analysis (GSEA). LBX2 expression levels were significantly upregulated in CRC samples compared with corresponding normal colorectal tissues (P<0.05). LBX2 upregulation was correlated with advanced tumor stage (III or IV), vascular invasion, lymphatic invasion and the male sex (all P<0.05). Kaplan-Meier analyses showed that high expression levels of LBX2 were associated with a less favorable overall survival (OS) and disease-free survival (DFS) in CRC (all P<0.05). Multivariate analyses further confirmed that LBX2 upregulation was an independent indicator of less favorable OS and DFS (all P<0.05). In addition, LBX2 DNA hypomethylation and microRNA (miR)-378a-3p downregulation correlated with LBX2 upregulation in CRC (all P<0.05). The downregulation of miR-378a-3p in CRC was also significantly associated with less favorable OS and DFS, as demonstrated using Kaplan-Meier analyses (all P<0.05). Moreover, GSEA indicated that 'VEGF signaling', 'Cell adhesion molecules CAMs', 'Toll-like receptor signaling' and 'Natural killer cell-mediated cytotoxicity' signaling pathways were enriched in the high LBX2 expressing cohort (all P<0.05). Thus, overexpression of LBX2 may be associated with the development of CRC and may serve as a novel prognostic marker and therapeutic target in CRC. The mechanisms of LBX2 upregulation in CRC are possibly associated with LBX2 DNA hypomethylation and miR-378a-3p downregulation. The potential mechanisms of LBX2 upregulation in CRC might be regulated via the 'Cell adhesion molecules CAMs', 'Toll-like receptor signaling' and 'Natural killer cell-mediated cytotoxicity' signaling pathways.]]></description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2020.11489</identifier><identifier>PMID: 32382328</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Analysis ; Colorectal cancer ; Datasets ; Development and progression ; Diseases ; DNA ; DNA methylation ; Endothelial growth factors ; Gene expression ; Genomes ; Genomics ; Health aspects ; Killer cells ; Male identity ; Medical prognosis ; MicroRNA ; MicroRNAs ; Morbidity ; Novels ; Oncology ; Prognosis ; Regression analysis ; Software ; Tumorigenesis ; Tumors ; Vascular endothelial growth factor</subject><ispartof>Oncology letters, 2020-06, Vol.19 (6), p.3751-3760</ispartof><rights>Copyright: © Huang et al.</rights><rights>COPYRIGHT 2020 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2020</rights><rights>Copyright: © Huang et al. 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-11a45fdce6b1dcc34696f2e6ecbb1e3a57443f6d89349e5fe321210bdd0836383</citedby><cites>FETCH-LOGICAL-c513t-11a45fdce6b1dcc34696f2e6ecbb1e3a57443f6d89349e5fe321210bdd0836383</cites><orcidid>0000-0002-1496-2409</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202318/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202318/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32382328$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Xiaodong</creatorcontrib><creatorcontrib>Yang, Yujie</creatorcontrib><creatorcontrib>Yang, Chao</creatorcontrib><creatorcontrib>Li, Huali</creatorcontrib><creatorcontrib>Cheng, Huangrong</creatorcontrib><creatorcontrib>Zheng, Yongbin</creatorcontrib><title>Overexpression of LBX2 associated with tumor progression and poor prognosis in colorectal cancer</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description><![CDATA[Colorectal cancer (CRC) is one of the most common carcinomas with high morbidity and mortality worldwide. However, the underlying molecular mechanisms of CRC are unclear. The aim of the present study was to establish the role that overexpression of LBX2 serves in CRC and to investigate the associated biological pathways. The difference in the expression levels of LBX2 between CRC tissues and adjacent normal colorectal tissues was assessed using the Oncomine database and Tumor Immune Estimation Resource. The expression levels of LBX2 and its prognostic significance in CRC were analyzed using a t-test and χ
test using data from The Cancer Genome Atlas database. The Kaplan-Meier method and Cox regression analysis were used to estimate the prognostic value of LBX2 in CRC. Furthermore, the potential mechanisms of LBX2 dysregulation and its underlying molecular mechanisms in CRC were investigated using Gene Set Enrichment Analysis (GSEA). LBX2 expression levels were significantly upregulated in CRC samples compared with corresponding normal colorectal tissues (P<0.05). LBX2 upregulation was correlated with advanced tumor stage (III or IV), vascular invasion, lymphatic invasion and the male sex (all P<0.05). Kaplan-Meier analyses showed that high expression levels of LBX2 were associated with a less favorable overall survival (OS) and disease-free survival (DFS) in CRC (all P<0.05). Multivariate analyses further confirmed that LBX2 upregulation was an independent indicator of less favorable OS and DFS (all P<0.05). In addition, LBX2 DNA hypomethylation and microRNA (miR)-378a-3p downregulation correlated with LBX2 upregulation in CRC (all P<0.05). The downregulation of miR-378a-3p in CRC was also significantly associated with less favorable OS and DFS, as demonstrated using Kaplan-Meier analyses (all P<0.05). Moreover, GSEA indicated that 'VEGF signaling', 'Cell adhesion molecules CAMs', 'Toll-like receptor signaling' and 'Natural killer cell-mediated cytotoxicity' signaling pathways were enriched in the high LBX2 expressing cohort (all P<0.05). Thus, overexpression of LBX2 may be associated with the development of CRC and may serve as a novel prognostic marker and therapeutic target in CRC. The mechanisms of LBX2 upregulation in CRC are possibly associated with LBX2 DNA hypomethylation and miR-378a-3p downregulation. The potential mechanisms of LBX2 upregulation in CRC might be regulated via the 'Cell adhesion molecules CAMs', 'Toll-like receptor signaling' and 'Natural killer cell-mediated cytotoxicity' signaling pathways.]]></description><subject>Analysis</subject><subject>Colorectal cancer</subject><subject>Datasets</subject><subject>Development and progression</subject><subject>Diseases</subject><subject>DNA</subject><subject>DNA methylation</subject><subject>Endothelial growth factors</subject><subject>Gene expression</subject><subject>Genomes</subject><subject>Genomics</subject><subject>Health aspects</subject><subject>Killer cells</subject><subject>Male identity</subject><subject>Medical prognosis</subject><subject>MicroRNA</subject><subject>MicroRNAs</subject><subject>Morbidity</subject><subject>Novels</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Regression analysis</subject><subject>Software</subject><subject>Tumorigenesis</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptks1vFCEYxidGY5u1R6-GxMR42XWAGRYuJm1TP5JNetHEGzLMO7s0DO8IM1X_-zJ2u3aNcIDA732Ah6coXtJyxaVi79CvWMnKFaWVVE-KU7pWbElLyZ4e5uvqpDhL6abMrRZUSvG8OOGMS8aZPC2-X99ChF9DhJQcBoId2Vx8Y8SkhNaZEVry0407Mk49RjJE3D6QJrRkwP1iwOQScYFY9BjBjsYTa4KF-KJ41hmf4Gw_LoqvH66-XH5abq4_fr483yxtTfm4pNRUdddaEA1treWVUKJjIMA2DQVu6nVV8U60UvFKQd0BZ5TRsmnbUnLBJV8U7-91h6npIQuFMRqvh-h6E39rNE4f7wS301u81evsIKezwNu9QMQfE6RR9y5Z8N4EwClpVmUDuZL5uovi9T_oDU4x5OfNFK1VrYT8S22NB-1Ch_lcO4vqc8EEZZWiKlOr_1C5t9A7iwE6l9ePCt48KtiB8eMuoZ_G_CnpGFzegzZiShG6gxm01HN8NHo9x0f_iU_mXz128EA_hIXfAY-BvzU</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Huang, Xiaodong</creator><creator>Yang, Yujie</creator><creator>Yang, Chao</creator><creator>Li, Huali</creator><creator>Cheng, Huangrong</creator><creator>Zheng, Yongbin</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1496-2409</orcidid></search><sort><creationdate>20200601</creationdate><title>Overexpression of LBX2 associated with tumor progression and poor prognosis in colorectal cancer</title><author>Huang, Xiaodong ; Yang, Yujie ; Yang, Chao ; Li, Huali ; Cheng, Huangrong ; Zheng, Yongbin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-11a45fdce6b1dcc34696f2e6ecbb1e3a57443f6d89349e5fe321210bdd0836383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Analysis</topic><topic>Colorectal cancer</topic><topic>Datasets</topic><topic>Development and progression</topic><topic>Diseases</topic><topic>DNA</topic><topic>DNA methylation</topic><topic>Endothelial growth factors</topic><topic>Gene expression</topic><topic>Genomes</topic><topic>Genomics</topic><topic>Health aspects</topic><topic>Killer cells</topic><topic>Male identity</topic><topic>Medical prognosis</topic><topic>MicroRNA</topic><topic>MicroRNAs</topic><topic>Morbidity</topic><topic>Novels</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Regression analysis</topic><topic>Software</topic><topic>Tumorigenesis</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><toplevel>online_resources</toplevel><creatorcontrib>Huang, Xiaodong</creatorcontrib><creatorcontrib>Yang, Yujie</creatorcontrib><creatorcontrib>Yang, Chao</creatorcontrib><creatorcontrib>Li, Huali</creatorcontrib><creatorcontrib>Cheng, Huangrong</creatorcontrib><creatorcontrib>Zheng, Yongbin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Xiaodong</au><au>Yang, Yujie</au><au>Yang, Chao</au><au>Li, Huali</au><au>Cheng, Huangrong</au><au>Zheng, Yongbin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overexpression of LBX2 associated with tumor progression and poor prognosis in colorectal cancer</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>19</volume><issue>6</issue><spage>3751</spage><epage>3760</epage><pages>3751-3760</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract><![CDATA[Colorectal cancer (CRC) is one of the most common carcinomas with high morbidity and mortality worldwide. However, the underlying molecular mechanisms of CRC are unclear. The aim of the present study was to establish the role that overexpression of LBX2 serves in CRC and to investigate the associated biological pathways. The difference in the expression levels of LBX2 between CRC tissues and adjacent normal colorectal tissues was assessed using the Oncomine database and Tumor Immune Estimation Resource. The expression levels of LBX2 and its prognostic significance in CRC were analyzed using a t-test and χ
test using data from The Cancer Genome Atlas database. The Kaplan-Meier method and Cox regression analysis were used to estimate the prognostic value of LBX2 in CRC. Furthermore, the potential mechanisms of LBX2 dysregulation and its underlying molecular mechanisms in CRC were investigated using Gene Set Enrichment Analysis (GSEA). LBX2 expression levels were significantly upregulated in CRC samples compared with corresponding normal colorectal tissues (P<0.05). LBX2 upregulation was correlated with advanced tumor stage (III or IV), vascular invasion, lymphatic invasion and the male sex (all P<0.05). Kaplan-Meier analyses showed that high expression levels of LBX2 were associated with a less favorable overall survival (OS) and disease-free survival (DFS) in CRC (all P<0.05). Multivariate analyses further confirmed that LBX2 upregulation was an independent indicator of less favorable OS and DFS (all P<0.05). In addition, LBX2 DNA hypomethylation and microRNA (miR)-378a-3p downregulation correlated with LBX2 upregulation in CRC (all P<0.05). The downregulation of miR-378a-3p in CRC was also significantly associated with less favorable OS and DFS, as demonstrated using Kaplan-Meier analyses (all P<0.05). Moreover, GSEA indicated that 'VEGF signaling', 'Cell adhesion molecules CAMs', 'Toll-like receptor signaling' and 'Natural killer cell-mediated cytotoxicity' signaling pathways were enriched in the high LBX2 expressing cohort (all P<0.05). Thus, overexpression of LBX2 may be associated with the development of CRC and may serve as a novel prognostic marker and therapeutic target in CRC. The mechanisms of LBX2 upregulation in CRC are possibly associated with LBX2 DNA hypomethylation and miR-378a-3p downregulation. The potential mechanisms of LBX2 upregulation in CRC might be regulated via the 'Cell adhesion molecules CAMs', 'Toll-like receptor signaling' and 'Natural killer cell-mediated cytotoxicity' signaling pathways.]]></abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>32382328</pmid><doi>10.3892/ol.2020.11489</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-1496-2409</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2020-06, Vol.19 (6), p.3751-3760 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7202318 |
| source | Spandidos Publications Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Analysis Colorectal cancer Datasets Development and progression Diseases DNA DNA methylation Endothelial growth factors Gene expression Genomes Genomics Health aspects Killer cells Male identity Medical prognosis MicroRNA MicroRNAs Morbidity Novels Oncology Prognosis Regression analysis Software Tumorigenesis Tumors Vascular endothelial growth factor |
| title | Overexpression of LBX2 associated with tumor progression and poor prognosis in colorectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T04%3A36%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overexpression%20of%20LBX2%20associated%20with%20tumor%20progression%20and%20poor%20prognosis%20in%20colorectal%20cancer&rft.jtitle=Oncology%20letters&rft.au=Huang,%20Xiaodong&rft.date=2020-06-01&rft.volume=19&rft.issue=6&rft.spage=3751&rft.epage=3760&rft.pages=3751-3760&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2020.11489&rft_dat=%3Cgale_pubme%3EA626124919%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2401595968&rft_id=info:pmid/32382328&rft_galeid=A626124919&rfr_iscdi=true |